SPA
ZNTL icon

Sherbrooke Park Advisers’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Sherbrooke Park Advisers’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,448
Closed -$116K – 1216
2024
Q3 		$116K Sell
31,448
-9,891
-24% -$35.9K 0.03% 823
2024
Q2 		$169K Buy
+41,339
New +$462K 0.03% 789

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Sherbrooke Park Advisers's ZNTL Position: Q4 2024 in Review

Sherbrooke Park Advisers sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2024, closing a stake of 31,448 shares — an estimated $116K sold.

Sherbrooke Park Advisers first reported a position in ZNTL in Q2 2024 and held it in 2 quarters. The position peaked at $169K in Q2 2024. 142 funds tracked by Wall St. Rank hold ZNTL as of Q4 2024.

  • Sherbrooke Park Advisers reported no remaining Zentalis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 31,448 Zentalis Pharmaceuticals shares in Q4 2024, an estimated $116K.
  • Sherbrooke Park Advisers first reported a position in Zentalis Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Zentalis Pharmaceuticals position peaked at $169K in Q2 2024.
  • 142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.